# Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Canonical URL: https://biopharmsignal.com/news/FATE/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ft819
Ticker: FATE
Company: Fate Therapeutics
Source: Fate Therapeutics
Published: 2026-05-05 12:30 EST
Original Source URL: https://ir.fatetherapeutics.com
## Summary

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation

## Article Body
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation
## Recent Company News
- 2026-06-01 12:30 EST — [Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-oncology-annual-meeting) — Source: Fate Therapeutics
- 2026-05-21 12:30 EST — [Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases](https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-presentations-at-2026-asco-and-eular-annual-meetings-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and-autoimmune-diseases) — Source: Fate Therapeutics
- 2026-05-13 12:30 EST — [Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Fate Therapeutics
- 2026-05-11 12:30 EST — [Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-ft819-clinical-activity-in-sle-without-the-use-of-conditioning-chemotherapy-at-the-2026-asgct-annual-meeting) — Source: Fate Therapeutics
- 2026-05-05 12:30 EST — [Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819](https://biopharmsignal.com/news/FATE/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ft819) — Source: Fate Therapeutics
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)